Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aramchol meglumine in Primary Sclerosing Cholangitis
NCT06095986Phase 2Withdrawn
- Sponsor
- Galmed Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aramchol in Primary Sclerosing Cholangitis (PSC), sponsored by Galmed Pharmaceuticals. Planned start Jun 2025; status: withdrawn.
02
Drugs
aramchol
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT06095986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06095986.